Vaxcyte Raises $100M Via Equity To Fund Development Of Lead Pneumococcal Vaccine Candidate

Vaxcyte Inc PCVX priced its previously announced offering of common stock and pre-funded warrants at $20.00 per share, and $19.999 per underlying share, respectively.

  • Vaxcyte is selling 2.5 million shares and pre-funded warrants to purchase 2.5 million shares of common stock in the offering.
  • The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $100.0 million.
  • The underwriters have an option to purchase additional 750,000 shares.
  • The offering will close on January 18, 2022.
  • BofA Securities, Jefferies, and Evercore ISI are acting as joint book-running managers. 
  • Cantor is acting as lead manager for the offering. Needham & Company is acting as co-manager for the offering.
  • Last week, the FDA signed off Vaxcyte's lead Investigational New Drug (IND) application for VAX-24, its lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate.
  • Vaxcyte expects to initiate the Phase 1/2 clinical proof-of-concept study in adults in Q1 of 2022 and announce topline immunogenicity results by the end of the year.
  • Price Action: PCVX shares are down 2.27% at $21.50 during the premarket session on the last check Thursday.
Posted In: BriefsPhase 1 TrialPhase 2 TrialPneumococcal DiseaseBiotechNewsHealth CareFinancingOfferingsSmall CapMoversTrading IdeasGeneral